Glenmark Pharma
Ticker > Company >

Glenmark Pharma share price

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK BSE: 532296 SECTOR: Pharmaceuticals & Drugs  2.76 L   1.39 K   224

2098.35
-32.35 (-1.52%)
BSE: 15 Sep 04:01 PM

Price Summary

Today's High

₹ 2145.35

Today's Low

₹ 2090.2

52 Week High

₹ 2286.15

52 Week Low

₹ 1274.7

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 59215.61 Cr.

Enterprise Value

₹ 59781.68 Cr.

No. of Shares

28.22 Cr.

P/E

39.83

P/B

2.38

Face Value

₹ 1

Div. Yield

0.12 %

Book Value (TTM)

₹  879.93

CASH

₹ 132.74 Cr.

DEBT

₹ 698.82 Cr.

Promoter Holding

46.65 %

EPS (TTM)

₹  52.69

Sales Growth

16.92%

ROE

6.78 %

ROCE

9.02%

Profit Growth

-68.84 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Glenmark Pharmaceuticals Ltd.

CANDID ALEX-P SYRUP SIBUTRIM GLINATE LEREZ VORTH-XT STRONAT ERDOZET DYCERIN FINTOP SIBET NITAZET-O ONABET ESOZ - D COLY-MONAS PALNOX AIRTEC-FB BORTRAC GEFTIB TAZRET EVERMIL GLUCAR ZINOX TACROZ FORTE FLEXILOR MIGNAR ASCORIL PLUS TACROZ

Index Presence

The company is present in 29Indices.

NIFTYMIDCAP

NIFTY Midcap 100
58486.1
  258.900000000001 (0.444637557704985%)

NIFTYALPHA

Nifty Alpha 50
51425.8
  190.450000000004 (0.371716012479673%)

NYMIDSML400MQ100

Nifty MidSmallcap400 Momentum Quality 100 Index
48956.75
  173.650000000001 (0.355963438157891%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
45048.05
  -135.049999999996 (-0.298894940807504%)

NT200ALP30

NIFTY200 Alpha 30
25305.25
  42.8499999999985 (0.169619671923482%)

NIFTY500

Nifty 500
23215.85
  25.5999999999985 (0.110391220448247%)

NIFTYPHARMA

Nifty Pharma
22198.7
  -142.5 (-0.637835031242728%)

NIFTYMIDCAP150

Nifty Midcap 150
21657.4
  90.2000000000007 (0.418227679068228%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
20083.95
  99.1000000000022 (0.495875625786546%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
17892.2
  59.8500000000022 (0.335625983114962%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
16318.75
  30.3999999999996 (0.1866364610289%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
16202.55
  38.7999999999993 (0.240043306782156%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
15710.35
  -15.8500000000004 (-0.100787221324927%)

NIFTYHEALTH

Nifty Healthcare Index
14666.7
  -81.0999999999985 (-0.549912529326402%)

NFT500EQUAL

Nifty 500 Equal Weight
14495.7
  74.9500000000007 (0.519737184265723%)

NIFTY200

Nifty 200
14017.9
  5.35000000000036 (0.0381800600176341%)

NIFTYTOTALMCAP

Nifty Total Market index
13068.9
  17.6499999999996 (0.135236088497259%)

MIDCAP

S&P Bse Mid Cap
46368.21
  183.909999999996 (0.398208915150811%)

BSE HC

S&P Bse Healthcare
44718.48
  -204.089999999997 (-0.454315058109978%)

BSE500

S&P Bse 500
36452.98
  34.3600000000006 (0.0943473421013863%)

MID150

S&P Bse 150 MidCap
16190.17
  61.6100000000006 (0.381993184760443%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
12171.18
  55.9500000000007 (0.461815417453915%)

BSE1000

Bse 1000
10864.2
  13.5600000000013 (0.124969587047419%)

LMI250

S&P Bse 250 LargeMidCap
10828.12
  4 (0.0369545053085174%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
10319.66
  72.75 (0.709970127579918%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

SPBSMOIP

S&P Bse Momentum
2252.15
  -2.21000000000004 (-0.0980322574921533%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year16.92%
3 Year4.26%
5 Year6.57%

Profit Growth

1 Year-68.84%
3 Year-6.93%
5 Year3.52%

ROE%

1 Year6.78%
3 Year13.02%
5 Year12.7%

ROCE %

1 Year9.02%
3 Year16.73%
5 Year15.2%

Debt/Equity

0.0285

Price to Cash Flow

100.57

Interest Cover Ratio

45.2004

CFO/PAT (5 Yr. Avg.)

0.34614204351757

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 46.65 0.00
Mar 2025 46.65 0.00
Dec 2024 46.65 0.00
Sep 2024 46.65 0.00
Jun 2024 46.65 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 45.2004.
  • The company has an efficient Cash Conversion Cycle of -149.6089 days.

 Limitations

  • The company has shown a poor profit growth of -6.93417747722542% for the Past 3 years.
  • The company has shown a poor revenue growth of 4.25761932934272% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 2329.54 2636.1 2251.28 2009.49 2394.93
Total Expenditure 1698.44 1857.47 1757.35 1668.97 1666.77
Operating Profit 631.1 778.63 493.93 340.53 728.16
Other Income 55.65 83.08 129.19 88.45 69.34
Interest 15.35 11.8 8.46 13.13 15.46
Depreciation 53.09 54.85 55.16 55.53 57.64
Exceptional Items 0 0 0 -179.17 -323.23
Profit Before Tax 618.31 795.06 559.49 181.16 401.17
Tax 164.58 200 145.69 33.4 70.94
Profit After Tax 453.73 595.06 413.8 147.76 330.23
Adjusted EPS (Rs) 16.08 21.09 14.66 5.24 11.7

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 7567.93 8141.58 8220.66 7891.12 9226.41
Total Expenditure 5677.59 6453.36 6747.9 6649.46 6982.23
Operating Profit 1890.34 1688.22 1472.77 1241.66 2244.18
Other Income 396.24 614.63 985.94 1168.02 356.37
Interest 265.9 236.04 206.82 277.11 48.73
Depreciation 150.82 159.7 184.15 202.16 218.63
Exceptional Items 73.89 430.33 -495.87 5070.33 -179.17
Profit Before Tax 1943.76 2337.45 1571.87 7000.75 2154.02
Tax 294.31 339.66 363.11 1833.46 543.67
Net Profit 1649.45 1997.79 1208.77 5167.29 1610.35
Adjusted EPS (Rs.) 58.46 70.8 42.84 183.11 57.07

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 28.22 28.22 28.22 28.22 28.22
Total Reserves 14781.29 16710.37 17849.25 22942.4 24475.74
Borrowings 3112.58 2571.74 2660.82 0 0
Other N/C liabilities 1150.51 1412.85 2394.32 3286.93 5020.36
Current liabilities 3934.34 4896.21 3991.95 5152.18 3245.91
Total Liabilities 23006.93 25619.39 26924.55 31409.72 32770.22
Assets
Net Block 1722.49 1752.33 1745.94 1756.25 1979.18
Capital WIP 93.31 101.17 159.07 175.5 121.34
Intangible WIP 38.09 7.87 13.27 22.17 33.22
Investments 6989.95 8559.39 10332.71 12964.79 15194.91
Loans & Advances 7818.27 9335.01 9934.57 10940.59 10659.14
Other N/C Assets 4.72 5.55 3.63 6.18 4.77
Current Assets 6340.11 5858.08 4735.35 5544.26 4777.67
Total Assets 23006.93 25619.39 26924.55 31409.72 32770.22
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1943.76 2337.45 1571.87 7000.75 2154.02
Adjustment 235.11 -617.5 122.48 -5884.79 154.2
Changes in Assets & Liabilities -599.61 -113.17 196.13 -740.31 -1136.55
Tax Paid -335.84 -390.72 -416.42 -871.1 -582.88
Operating Cash Flow 1243.42 1216.07 1474.06 -495.45 588.8
Investing Cash Flow -1235.19 -897.02 -431.52 3197.17 -489.9
Financing Cash Flow -80.79 -305.12 -978.5 -2666.45 -95.41
Net Cash Flow -72.57 13.93 64.05 35.27 3.49

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 46.65 46.65 46.65 46.65 46.65
blanche elizabeth saldanh... 0.39 0.39 0.39 0.39 0.39
cherylann maria pinto 0.27 0.27 0.27 0.27 0.27
glenn mario saldanha 0.35 0.35 0.35 0.35 0.35
neha saldanha 0.01 0.01 0.01 0.01 0.01
robin joseph pinto 0.18 0.18 0.18 0.18 0.18
saldanha family trust 45.45 45.45 45.45 45.45 45.44
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 53.35 53.35 53.35 53.35 53.35
3p india equity fund 1 - - 1.02 1.02 1.02
amansa holdings private l... - - - - 1.44
ashish dhawan 2.55 2.55 1.88 1.77 1.24
government pension fund g... 3.25 3.25 3.25 3.25 3.21
hdfc mutual fund - hdfc n... - - - 4.27 5.24
invesco india midcap fund... - 1.07 - 1.41 2.02
investor education and pr... 0.09 0.09 0.09 0.09 0.09
mirae asset arbitrage fun... - - - 3.53 2.90
smallcap world fund, inc 3.13 3.10 3.38 3.21 2.11
ellipsis partners llc 1.68 1.31 1.17 1.11 -
aditya birla sun life tru... 1.50 1.15 1.16 - -
hdfc mutual fund - hdfc m... 3.63 - 3.46 - -
invesco india manufacturi... - - 1.17 - -
mirae asset large & midca... - - 3.55 - -
hdfc mutual fund-hdfc arb... - 3.42 - - -
mirae asset elss tax save... - 2.80 - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
Credit INDIA RATINGS & RESEARCH
Credit INDIA RATINGS & RESEARCH
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research Report By:
Research HDFC Securities
Research ICICI Securities Limited
Research Motilal Oswal
Research Reliance Securities
Research Prabhudas Lilladhar
Research HDFC Securities
Research Geojit BNP Paribas

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q3FY25
Concall Q3FY25
Concall Q1FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q3FY24
Presentation Q3FY19
Presentation Q2FY24
Presentation Q1FY26
Presentation Q1FY24

Company News

Glenmark Pharmaceuticals informs about upfront payment received 9 Sep, 12:13 PM Glenmark Pharmaceuticals initiates multi-country Phase 3 Clinical Trial for Envafolimab 5 Sep, 12:41 PM Glenmark Pharmaceuticals informs about media release 2 Sep, 1:04 PM Glenmark Pharmaceuticals’ arm to launch Eribulin Mesylate Injection 2 Sep, 12:28 PM Glenmark Pharma makes remaining investment of Rs 0.24 crore in O2 Renewable Energy XXIV 21 Aug, 11:08 AM Glenmark Pharmaceuticals’ arm to launch Micafungin for Injection 19 Aug, 12:22 PM Glenmark Pharmaceuticals informs about media release 19 Aug, 11:05 AM Glenmark Pharmaceuticals reports 86% drop in Q1 consolidated net profit 16 Aug, 4:05 PM Glenmark Pharma - Quaterly Results 14 Aug, 5:14 PM Glenmark Pharma - Quaterly Results 14 Aug, 5:14 PM Glenmark Pharma - Quaterly Results 14 Aug, 5:14 PM Glenmark Pharmaceuticals gets warning letter for Indore facility 14 Jul, 10:23 AM Glenmark Pharmaceuticals’ arm enters into licensing agreement with AbbVie 11 Jul, 12:21 PM Glenmark Pharmaceuticals informs about details of KMP 1 Jul, 5:36 PM Glenmark Pharmaceuticals launches TEVIMBRA in India 24 Jun, 12:30 PM Glenmark Pharmaceuticals informs about media release 24 Jun, 10:05 AM Glenmark Pharmaceuticals informs about disclosure 19 Jun, 9:55 AM USFDA concludes GMP inspection at Glenmark Pharmaceuticals’ USA manufacturing facility 18 Jun, 10:37 AM Glenmark Pharmaceuticals informs about updates 18 Jun, 9:55 AM Glenmark Pharmaceuticals to launch zanubrutinib in India 9 Jun, 12:00 PM Glenmark Pharmaceuticals informs about media release 9 Jun, 11:22 AM Glenmark Pharmaceuticals reports consolidated net profit of Rs 4.38 crore in Q4 26 May, 12:20 PM Glenmark Pharma - Quaterly Results 23 May, 7:59 PM Glenmark Pharma - Quaterly Results 23 May, 7:59 PM Glenmark Pharmaceutical informs about earnings call 19 May, 11:42 AM Glenmark Pharmaceuticals’ arm to launch generic Adderall tablets 17 Apr, 12:21 PM Glenmark Pharmaceuticals’ arm recalls over 25 products in US market 14 Apr, 11:16 AM Glenmark’s US arm recalling 8,160 bottles of chlorpromazine hydrochloride tablets in US 11 Apr, 3:08 PM Glenmark Pharmaceuticals informs about appointment of senior management personnel 7 Apr, 9:32 AM Glenmark Pharmaceuticals informs about press release 1 Apr, 11:46 AM Glenmark’s US arm launches Vancomycin Hydrochloride for injection USP 1 Apr, 10:07 AM Glenmark Pharmaceuticals informs about disclosure 29 Mar, 11:57 AM Glenmark Pharmaceuticals informs about newspaper advertisement 27 Mar, 5:22 PM Glenmark’s US arm gets USFDA’s approval for Olopatadine Hydrochloride Ophthalmic Solution 21 Mar, 9:35 AM Glenmark Pharmaceuticals launches Empagliflozin in India 12 Mar, 1:00 PM Glenmark Pharmaceuticals informs about media release 12 Mar, 12:17 PM Glenmark Pharmaceuticals’ arm launches Polyethylene Glycol 3350 10 Mar, 9:35 AM Glenmark Pharmaceuticals informs about media release 10 Mar, 9:22 AM Glenmark Pharmaceuticals’ US arm recalls around 14.76 lakh bottles of Atomoxetine Capsules 3 Mar, 10:25 AM Glenmark Pharmaceuticals informs about media release 3 Mar, 9:29 AM Glenmark Pharmaceuticals’ arm acquires, launches Acetylcysteine Injection 3 Mar, 9:22 AM Glenmark Pharmaceutical informs about media release 27 Feb, 9:38 AM Glenmark Pharmaceuticals’ US arm launches Epinephrine Injection 27 Feb, 9:08 AM Glenmark Pharmaceuticals turns black in Q3 17 Feb, 4:41 PM Glenmark Pharmaceuticals informs about conference call 17 Feb, 2:08 PM Glenmark Pharma - Quaterly Results 14 Feb, 6:19 PM Glenmark Pharma - Quaterly Results 14 Feb, 6:19 PM Glenmark Pharma - Quaterly Results 14 Feb, 6:19 PM Glenmark Pharmaceuticals informs about media release 14 Feb, 10:36 AM Glenmark Pharmaceuticals’ US arm launches Latanoprost Ophthalmic Solution 14 Feb, 10:30 AM

Glenmark Pharma Stock Price Analysis and Quick Research Report. Is Glenmark Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Glenmark Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Glenmark Pharma has a PE ratio of 39.8481613285884 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Glenmark Pharma has ROA of 5.0182% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Glenmark Pharma has a Current ratio of 1.4719.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Glenmark Pharma has a ROE of 6.7848%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Glenmark Pharma has a Debt to Equity ratio of 0.0285 which means that the company has low proportion of debt in its capital.

  • Sales growth: Glenmark Pharma has reported revenue growth of 16.9214% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Glenmark Pharma for the current financial year is 24.3234393792861%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Glenmark Pharma is Rs 2.5 and the yield is 0.1191%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Glenmark Pharma is Rs 52.6875. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Glenmark Pharma in Ticker for free. Also, one can get the intrinsic value of Glenmark Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Glenmark Pharma FAQs

Q1. What is Glenmark Pharma share price today?
Ans: The current share price of Glenmark Pharma is Rs 2099.5.

Q2. What is the market capitalisation of Glenmark Pharma?
Ans: Glenmark Pharma has a market capitalisation of Rs 59248.05984955 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Glenmark Pharma?
Ans: The PE ratio of Glenmark Pharma is 39.8481613285884 and the P/B ratio of Glenmark Pharma is 2.38598796039226, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Glenmark Pharma share?
Ans: The 52-week high share price of Glenmark Pharma is Rs 2284.8, and the 52-week low share price of Glenmark Pharma is Rs 1275.5.

Q5. Does Glenmark Pharma pay dividends?
Ans: Currently, Glenmark Pharma pays dividends. Dividend yield of Glenmark Pharma is around 0.1191%.

Q6. What are the face value and book value of Glenmark Pharma shares?
Ans: The face value of Glenmark Pharma shares is Rs 1, while the book value per share of Glenmark Pharma is around Rs 879.929. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Glenmark Pharma?
Ans: Glenmark Pharma has a total debt of Rs 698.82 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Glenmark Pharma?
Ans: The ROE of Glenmark Pharma is 6.7848% and ROCE of Glenmark Pharma is 9.022%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Glenmark Pharma a good buy for the long term?
Ans: The Glenmark Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Glenmark Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Glenmark Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Glenmark Pharma’s financials?
Ans: You can review Glenmark Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Glenmark Pharma

Glenmark Pharmaceuticals Ltd Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis 

 

Welcome to the Glenmark Pharmaceuticals Ltd stock analysis page tailored for college student stock investors seeking comprehensive insights. In this section, we will delve into various aspects of Glenmark Pharmaceuticals Ltd, including its share price, balance sheet, annual report, dividend, quarterly results, stock price, price chart, news, concall transcripts, investor presentations, promoters, and shareholders. Our objective is to equip you with valuable information to make informed investment decisions.

Glenmark Pharmaceuticals Ltd Share Price Analysis 

Evaluate the share price of Glenmark Pharmaceuticals Ltd to gauge its market performance. Utilize Ticker pre-built screening tools to assess the current stock price and compare it with industry peers. Leverage our platform's market trends and indicators to aid your analysis as a college student stock investor seeking to assess the potential of this stock.

Glenmark Pharmaceuticals Ltd Balance Sheet Evaluation 

Evaluate the balance sheet of Glenmark Pharmaceuticals Ltd to understand the company's financial stability and performance. Leverage our premium features, including DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis, to calculate the fair value based on the balance sheet. These tools provide a comprehensive view of the company's financials, empowering you to make informed investment decisions.

Glenmark Pharmaceuticals Ltd Annual Report Review 

Access the annual reports of Glenmark Pharmaceuticals Ltd for valuable insights into the company's performance, strategies, and future prospects. Downloadable versions of the annual reports are available on Ticker, facilitating thorough analysis. College student stock investors will find these reports invaluable for understanding the company's long-term vision and growth trajectory.

Glenmark Pharmaceuticals Ltd Dividend Analysis 

Evaluate the dividend policy and history of Glenmark Pharmaceuticals Ltd. Ticker pre-built screening tools assist in analyzing the company's dividend payment history and potential. Monitor the dividend yield to assess the income potential associated with this stock. Dividend analysis is essential for college student stock investors, as it provides insights into how the company rewards its shareholders.

Glenmark Pharmaceuticals Ltd Quarterly Results Examination 

Analyze the quarterly financial results of Glenmark Pharmaceuticals Ltd to evaluate its performance and growth trends. Our premium features, such as DCF Analysis, Earnings Multiple Approach, and DuPont Analysis, facilitate fair value calculations based on the quarterly results. This analysis delves into the company's revenue, expenses, and profitability.

Glenmark Pharmaceuticals Ltd Stock Price Monitoring 

Stay updated on the stock price of Glenmark Pharmaceuticals Ltd and track market trends. Our platform provides a detailed stock price chart, enabling historical data analysis and identification of patterns and trends. Understanding the stock's performance over time is crucial for college student stock investors seeking to make well-informed investment decisions.

Glenmark Pharmaceuticals Ltd Price Chart Analysis 

Analyze the price chart of Glenmark Pharmaceuticals Ltd to identify patterns and trends that can influence investment decisions. Ticker user-friendly interface allows for visual exploration of the stock's historical performance, enhancing understanding of market dynamics. Utilize this information to identify potential entry and exit points.

Glenmark Pharmaceuticals Ltd News Updates 

Stay updated with the latest news articles about Glenmark Pharmaceuticals Ltd. Ticker dedicated news section on the website offers valuable information on the company's recent developments, market trends, and industry updates. Staying informed is pivotal for college student stock investors looking to make sound investment decisions amid the dynamic market landscape.

Glenmark Pharmaceuticals Ltd Conference Call Transcripts 

Access conference call transcripts of Glenmark Pharmaceuticals Ltd to gain insights into the company's operations, strategies, and future plans. These transcripts comprehensively outline key discussions and announcements made during the company's conference calls. Utilize this information to gain a deeper understanding of the company's direction and prospects.

Glenmark Pharmaceuticals Ltd Investor Presentations 

Explore investor presentations of Glenmark Pharmaceuticals Ltd to obtain valuable insights into the company's growth potential and investment opportunities. These presentations provide an overview of the company's value proposition, strategies, and financial performance. Analyzing investor presentations can offer college student stock investors a better understanding of the company's vision and plans.

Glenmark Pharmaceuticals Ltd Promoters & Shareholders 

Understand the ownership structure of Glenmark Pharmaceuticals Ltd by reviewing its key promoters and major shareholders. Gain insights into ownership concentration and potential alignment of interests. Ticker provides detailed information about the company's promoters and major shareholders, enabling informed investment decisions and understanding of the key stakeholders driving the company's growth.

Glenmark Pharmaceuticals Ltd ROCE

Glenmark Pharmaceuticals Ltd's Return on Capital Employed (ROCE) is a vital financial metric that evaluates the company's profitability and efficiency in utilizing its capital investments. Our stock analysis page provides comprehensive ROCE data for Glenmark Pharmaceuticals Ltd, allowing investors to assess the company's ability to generate returns from the capital employed. By analyzing this ratio, investors can gain insights into the company’s financial performance. Access the detailed ROCE information for Glenmark Pharmaceuticals Ltd in the financials table or ratio section on this page.

Glenmark Pharmaceuticals Ltd EBITDA

Glenmark Pharmaceuticals Ltd's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is a key measure for evaluating the company's operational performance and profitability. Our stock analysis page offers comprehensive EBITDA data for Glenmark Pharmaceuticals Ltd, enabling investors to assess the company's core earnings and financial health. Access the detailed EBITDA figures for Glenmark Pharmaceuticals Ltd in the financials table or ratio section on this page.

Glenmark Pharmaceuticals Ltd DPS

Glenmark Pharmaceuticals Ltd's Dividends Per Share (DPS) indicate the portion of profits distributed to shareholders as dividends. Monitoring DPS is essential for investors seeking a consistent income from dividends. Our stock analysis page features the DPS data for Glenmark Pharmaceuticals Ltd, enabling investors to track the company's dividend history and payout ratio. Access the detailed DPS information for Glenmark Pharmaceuticals Ltd in the financials table or ratio section on this page.

Glenmark Pharmaceuticals Ltd EPS

Earnings Per Share (EPS) is a fundamental financial metric that measures Glenmark Pharmaceuticals Ltd's profitability on a per-share basis. Our stock analysis page provides detailed EPS information for Glenmark Pharmaceuticals Ltd, allowing investors to assess the company's earnings performance and growth potential. Access the comprehensive EPS figures for Glenmark Pharmaceuticals Ltd in the financials table or ratio section on this page to make informed investment decisions. 

Glenmark Pharmaceuticals Share Capital Stability

Glenmark Pharmaceuticals has shown a constant Share Capital figure at Rs 28.22 Cr from March 2020 to March 2024, indicating a stable equity structure without any dilution to the shareholders' value during this period.

Glenmark Pharmaceuticals Reserves Growth

The Total Reserves of Glenmark Pharmaceuticals have seen a significant rise from Rs 13,198.05 Cr in March 2020 to Rs 22,942.40 Cr by March 2024. This robust increase in reserves underscores the company's solid financial health and its capability to support future growth.

Reducing Debt in Glenmark Pharmaceuticals' Financials

A notable aspect of Glenmark Pharmaceuticals' balance sheet is the reduction of Borrowings to zero by March 2024, down from Rs 3,131.17 Cr in March 2020. This debt clearance is a positive sign, reflecting the company's strong focus on achieving a debt-free status, enhancing its financial resilience.

Investments and Asset Growth at Glenmark Pharmaceuticals

Glenmark Pharmaceuticals' Investments have nearly tripled, moving from Rs 4,713.93 Cr in March 2020 to Rs 12,964.79 Cr by March 2024. Additionally, the consistent growth in Assets, from Rs 19,738.33 Cr in March 2020 to Rs 31,409.72 Cr in March 2024, highlights the company's aggressive expansion and reinvestment in its future.

This data is an analysis for the Standalone Balance sheet of Glenmark Pharmaceuticals. Investors looking into the pharmaceutical sector can also explore broader market trends on NSE/BSE indices, upcoming IPOs, or sectoral analyses for a comprehensive investment strategy.

Read More
X